Kim Shannon Hk, Habashy David, Pathan Sana, Tse Vincent, Collins Ruth, Chan Lewis
Department of Urology, Concord Repatriation General Hospital, Sydney, Australia.
Department of Surgery, University of Sydney, Sydney, Australia.
Int Neurourol J. 2016 Mar;20(1):40-6. doi: 10.5213/inj.1630450.225. Epub 2016 Mar 16.
To investigate the efficacy and safety of repeated botulinum toxin type-A (BTX-A) injections for patients with drug-refractory nonneurogenic overactive bladder (NNOAB) and explore factors predictive of outcome.
Data were collected from all patients receiving repeated BTX-A injections for drug-refractory NNOAB between 2004 and 2012. Trigone-sparing injections were administered under sedation with antibiotic prophylaxis. Patient characteristics including age, sex, preoperative urodynamics, injection number, BTX-A dose, complications, and patient global impression of improvement (PGI-I) scores were collected. Correlations between patient factors and outcomes were assessed by using Pearson's chi-square tests.
Fifty-two patients with a mean age of 67.4 years (range, 26-93 years) received 140 BTX-A injections in total; 33 (64%), 15 (29%), and 4 patients (7%) received 2, 3 to 4, and 5 to 8 injections, respectively. Mean follow-up time was 49 months (range, 9-101 months). Nine patients developed urinary tract infection; additionally, 3 patients experienced transient urinary retention. Median PGI-I score was 2 out of 7 (interquartile range [IQR], 2). For 46 patients, the PGI-I score remained stable with the administration of each injection. Pearson chi-square tests revealed that male patients or reduced bladder compliance was associated with a higher (worse) PGI-I score. Median PGI-I scores for men and women were 3 (IQR, 1) and 2 (IQR, 1), respectively; additionally, median PGI-I scores for those with normal bladder compliance and those with reduced bladder compliance were 2 (IQR, 2) and 4.5 (IQR, 1), respectively. Median PGI-I scores and complication rates were the same in the older patient (≥70 years) and younger (<70 years) patient cohorts.
Efficacy is maintained with repeated BTX-A injections. Patients including the elderly show a good degree of tolerability with a low complication rate. Male patients or reduced bladder compliance is associated with poorer outcomes.
探讨重复注射A型肉毒毒素(BTX-A)治疗药物难治性非神经源性膀胱过度活动症(NNOAB)患者的疗效和安全性,并探索预测治疗结果的因素。
收集2004年至2012年间所有接受重复BTX-A注射治疗药物难治性NNOAB患者的数据。在镇静及预防性使用抗生素的情况下进行保留三角区注射。收集患者特征,包括年龄、性别、术前尿动力学检查结果、注射次数、BTX-A剂量、并发症以及患者总体改善印象(PGI-I)评分。采用Pearson卡方检验评估患者因素与治疗结果之间的相关性。
52例平均年龄为67.4岁(范围26 - 93岁)的患者共接受了140次BTX-A注射;分别有33例(64%)、15例(29%)和4例(7%)接受了2次、3至4次以及5至8次注射。平均随访时间为49个月(范围9 - 101个月)。9例患者发生尿路感染;此外,3例患者出现短暂性尿潴留。PGI-I评分中位数为7分中的2分(四分位间距[IQR],2)。对于46例患者,每次注射后PGI-I评分保持稳定。Pearson卡方检验显示男性患者或膀胱顺应性降低与较高(较差)的PGI-I评分相关。男性和女性的PGI-I评分中位数分别为3分(IQR,1)和2分(IQR,1);此外,膀胱顺应性正常者和膀胱顺应性降低者的PGI-I评分中位数分别为2分(IQR,2)和4.5分(IQR,1)。老年患者(≥70岁)和年轻患者(<70岁)队列的PGI-I评分中位数和并发症发生率相同。
重复注射BTX-A可维持疗效。包括老年患者在内的患者耐受性良好,并发症发生率低。男性患者或膀胱顺应性降低与较差的治疗结果相关。